ArticleRespiratory research2026
TGM2-TUFM promotes acquired resistance to EGFR-TKIs in EGFR-mutated NSCLC through p62-mediated lipophagy.
Article in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundAcquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) remains the leading cause of treatment failure in advanced non-small cell lung cancer (NSCLC) patients harboring sensitizing EGFR mutations. This study aims to investigate the underlying resistance mechanisms in EGFR-mutated NSCLC.
methodsAnalyze the differential genes in the transcriptome sequencing data of EGFR-TKi-sensitive and -resistant cell lines, and use the GDC database to analyze the prognosis. qRT‒PCR, western blotting, and immunohistochemistry were used to detect the expression of TGM2 in EGFR-TKI-sensitive and -resistant NSCLC cells and tissue samples. The effects and molecular mechanisms of TGM2 on EGFR-TKI resistance were verified by CCK-8, flow cytometry, western blotting, mouse xenograft models, gene enrichment analysis, and mass spectrometry.
resultsOur study found that TGM2 was highly expressed in EGFR-TKI-resistant NSCLC cells and tissue samples. Its increased expression was associated with shorter survival time in NSCLC patients. Transglutaminase 2 (TGM2) overexpression renders EGFR-sensitive mutated NSCLC cells resistant to EGFR-TKIs in culture and in murine xenograft models. Mechanistically, we determined that TGM2 promotes lipophagy and fatty acid oxidation (FAO) by inhibiting the ubiquitin-mediated degradation of elongation factor Tu, mitochondrial (TUFM), thereby contributing to drug resistance in NSCLC. Furthermore, we found that TGM2 promotes the formation of p62 (sequestosome 1) bodies through TUFM, and these p62 bodies bind to lipid droplets (LDs)-associated protein perilipin 2 (PLIN2) to enhance lipophagy, revealing a novel pathway for TGM2-facilitated LD breakdown. Notably, treatment with the autophagy inhibitor chloroquine (CQ) and the FAO inhibitor etomoxir reversed TGM2-mediated EGFR-TKI resistance.
conclusionsOur study revealed that TGM2 is a potential therapeutic target or biomarker for predicting acquired EGFR-TKI resistance in EGFR-mutated NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.